Peptide-based anticancer vaccines

Poorly biodegradable, incomplete Freund’s adjuvant (IFA)-based anticancer vaccines primed CD8+ T cells that did not localize to the tumor site but to the persisting, antigen-rich vaccination site, which became a T-cell graveyard. Short-lived, water-based formulations and the provision of immunostimulatory molecules overcame this issue, resulting in tumor suppression. Here, we discuss the implications of these findings for the development of therapeutic anticancer vaccines.

• Publication year

  2013

• Venue

  Oncoimmunology

• Publication date

  2013-04-30

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.4161/onci.24743PMID 24073366PMCID 3782014
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Persistent antigen at vaccination sites induces tumor-specific CD8+ T cell sequestration, dysfunction and deletion

  2013cited by this paper
• TCR signaling requirements for activating T cells and for generating memory

  2012cited by this paper
• Cancer immunotherapy comes of age

  2011cited by this paper
• Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion

  2011cited by this paper
• Duration of Antigen Availability Influences the Expansion and Memory Differentiation of T Cells

  2011cited by this paper
• Preoperative CTLA-4 Blockade: Tolerability and Immune Monitoring in the Setting of a Presurgical Clinical Trial

  2010cited by this paper
• Tumor Progression Can Occur despite the Induction of Very High Levels of Self/Tumor Antigen-Specific CD8+ T Cells in Patients with Melanoma

  2005cited by this paper
• Cancer immunotherapy: moving beyond current vaccines

  2004cited by this paper
• Preferential Accumulation of Antigen-specific Effector CD4 T Cells at an Antigen Injection Site Involves CD62E-dependent Migration but Not Local Proliferation

  2003cited by this paper

• Recent Advances in Cancer Vaccines: Challenges, Achievements, and Futuristic Prospects

  2022cites this paper
• Therapeutic cancer vaccines for pediatric malignancies: advances, challenges, and emerging technologies

  2021cites this paper
• Exploiting Tumor Neoantigens to Target Cancer Evolution: Current Challenges and Promising Therapeutic Approaches.

  2021cites this paper
• Deciphering Human Leukocyte Antigen Susceptibility Maps From Immunopeptidomics Characterization in Oncology and Infections

  2021influential citation
• Anticancer effects of chemokine-directed antigen delivery to a cross-presenting dendritic cell subset with immune checkpoint blockade

  2020cites this paper
• A new synthetic toll-like receptor 1/2 ligand is an efficient adjuvant for peptide vaccination in a human volunteer

  2019cites this paper
• In silico epitope identification of unique multidrug resistance proteins from Salmonella Typhi for vaccine development

  2019cites this paper
• In Silico Design and Evaluation of Acinetobacter baumannii Outer Membrane Protein a Antigenic Peptides As Vaccine Candidate in Immunized Mice.

  2019cites this paper
• The Sulfated Polysaccharides of Brown Algae and Products of Their Enzymatic Transformation as Potential Vaccine Adjuvants

  2018cites this paper
• Photochemical Internalization of Peptide Antigens Provides a Novel Strategy to Realize Therapeutic Cancer Vaccination

  2018cites this paper
• Vaccines Developed for Cancer Immunotherapy

  2018cites this paper
• Vaccination with High-Affinity Epitopes Impairs Antitumor Efficacy by Increasing PD-1 Expression on CD8+ T Cells

  2017cites this paper
• A pilot study of the immunogenicity of a 9-peptide breast cancer vaccine plus poly-ICLC in early stage breast cancer

  2017cites this paper
• Microparticles and Nanoparticles for Cancer-Targeting Vaccines

  2017cites this paper
• Caractérisation topologique d'interactions non-covalentes inter- et intramoléculaires

  2017cites this paper
• Enhancement of Adjuvant Functions of Natural Killer T Cells Using Nanovector Delivery Systems: Application in Anticancer Immune Therapy

  2017cites this paper
• Safety and Immunological Efficacy of a DNA Vaccine Encoding the Androgen Receptor Ligand‐Binding Domain (AR‐LBD)

  2017cites this paper
• Novel Treatments in Development for Melanoma.

  2016cites this paper
• In silico identification of outer membrane protein (Omp) and subunit vaccine design against pathogenic Vibrio cholerae

  2016cites this paper
• Trial watch: Naked and vectored DNA-based anticancer vaccines

  2015cites this paper
• Trial Watch: Peptide-based anticancer vaccines

  2015cites this paper
• Combining Immunotherapy with Oncogene-Targeted Therapy: A New Road for Melanoma Treatment

  2015cites this paper
• A tumor lysate is an effective vaccine antigen for the stimulation of CD4+ T-cell function and subsequent induction of antitumor immunity mediated by CD8+ T cells

  2015cites this paper
• Could mycobacterial Hsp70-containing fusion protein lead the way to an affordable therapeutic cancer vaccine?

  2015cites this paper
• Classification of current anticancer immunotherapies

  2014cites this paper
• Cancer vaccines: Trafficking of tumor-specific T cells to tumor after therapeutic vaccination.

  2014cites this paper
• Peptide-Based Immunotherapeutics and Vaccines

  2014cites this paper
• Adjuvants in the Driver’s Seat: How Magnitude, Type, Fine Specificity and Longevity of Immune Responses Are Driven by Distinct Classes of Immune Potentiators

  2014cites this paper